Distant Recurrence-Free Survival Associated With Tamoxifen in Postmenopausal Patients With Luminal A or B Breast Cancer
This secondary analysis of the Stockholm Tamoxifen (STO-3) clinical trial, which was conducted from 1976 to 1990, assessed the long-term survival associated with tamoxifen therapy in postmenopausal patients with luminal A or B breast cancer tumor subtypes.